LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?